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future then guinea pig, rabbit or human tissue may be used 
without either of the latter three having clear superiority over 
the other. 
In pemphigus foliaceus a positive statistical correlation be-
tween disease severity and titer was obtained with rabbit esoph-
agus only. The reason for the lack of statistical correlation for 
the other substrates may relate to the small number of patients 
studied and/or the wide variations in titers in patients with 
pemphigus foliaceus. 
It is very important to emphasize that whichever substrate is 
used, there are some patients with either pemphigus vulgaris or 
pemphigus foliaceus in whom antibody titers may be low in the 
presence of extensive disease or in whom antibody titers may 
be high in the presence of minimal or no active disease. Thus 
as suggested in a recent study* in a large group of patients with 
pemphigus, the use of antibody titer to monitor disease activity 
and therapy in an individual patient may not be justifiable. 
Three distinct staining patterns were observed when sera 
from patients with active pemphigus were tested by indirect IF. 
The most common pattern which was observed on all substrates 
was bright intercellular fluorescence which was distributed 
throughout the malpigian layer of the epidermis. This pattern 
is regarded by some authors as characteristic of pemphigus 
[4,9,10]. Dull intercellular fluorescence was observed with some 
sera. The titer of these sera was always low (1:20) and staining 
was always limited to the lower epithelial layers. The dull 
fluorescence pattern may represent pemphigus-like antibodies 
as suggested by Chorzelski and Beutner [3]. Pemphigus-like 
antibodies have also been described in patients with extensive 
burns [11], penicillin allergy [12], trichopyton rubrum infection 
[13], cicatrical pemphigoid [14], and bullous pemphigoid [15]. 
Some of these antibodies may be removed by absorption of the 
sera with the appropriate antigen. Since the sera which pro-
duced dull fluorescence had been absorbed with red blood cell 
antigen and all sera were obtained from patients known to have 
active pemphigus, they were considered specific for pemphigus 
and were included in the statistical analysis. Epithelial nuclear 
staining was observed in 5 sera from 2 patients at a time when 
clinical remission of their disease had occurred. These anti-
bodies are not considered specific for pemphigus and may be 
removed by appropriate absorption [3]. 
In conclusion, indirect IF testing of sera from patients with 
either pemphigus vulgaris or foliaceus produces positive inter-
cellular staining on a variety of epithelial substrates. Use of 
these intercellular antibody titers to monitor disease activity 
may not be justifiable in an individual patient because of wide 
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variations in titer, however, there is a positive statistical corre-
lation between disease severity and titer when groups of pa-
tients are considered. Isolation and purification ofthe epithelial 
antigen in pemphigus may prove useful in developing a more 
reliable serological test for the diagnosis and monitoring of 
patients with pemphigus. 
The authors wish to acknowledge the expert technical assistance of 
Ms. Anita B. Ramsay. Walter F. Lever, M.D. kindly provided the serum 
samples used in this study. Statistical evaluation was performed by 
Herbert L. Cayne, Ph.D., Division of Biostatistics, Boston University 
School of Medicine. 
REFERENCES 
1. Beutner EH, Jordon RE: Demonstration of skin antibodies in sera 
of pemphigus vulgaris patients by indirect immuno,fluorescence 
staining. Proc Soc Exp Bioi Med 117:505-510, 1964 
2. Beutner EH: Autosensitization in Pemphigus and Bullous Pemphi-
goid. Charles C Thomas Co., Springfield, IL, 1970, chapter I, P 
11; and chapter 5, pp 69-81 
3. Chorzelski TP, Beutner EH: Factors contributing to occasional 
failures in demonstration of pemphigus antibodies by the im-
munofluorescence test. J Invest Dermatol 53:188-191, 1969 
4. Beutner EH, Lever WF, Witebsky E , Jordon RE, Chertock B: 
Autoantibodies in pemphigus vulgaris: Response to an intercel-
lular substance of epidermis. JAMA 192:682-688, 1965 
5. Chorzelski TP, von Weiss JF, Lever WF: Clinical significance of 
autoantibodies in pemphigus. Arch Dermatol 93:570-576, 1966 
6. Sams WM, Jordon RE: Correlation of pemphigoid and pemphigus 
antibody titers with activity of disease. Br J Dermatol 84:7-13, 
1971 
7. Lever WF, Schaumberg-Lever G: Immunosuppressants and pred-
nisone in pemphigus vulgaris. Arch DermatoI113:1236-1241, 1977 
8. Colton T : Statistics in Medicine. Little, Brown Co., Boston, MA, 
1974, P 223 
9. Waldorf DS, Smith CW, Strauss AJ : Immunofluorescent studies in 
pemphigus vulgaris: Conflrmatory observations and evaluation 
of technical considerations. Arch Dermatol 93:28-33, 1966 
10. Tuffanelli D: Cutaneous immunopathology: Recent observations, J 
Invest Dermatol 65:143-153, 1975 
11. Quismorio FP, Bland SL, Friou GJ: Autoimmunity in thermal 
injury: Occurrence of rheumatoid factors, antinuclear antibodies 
and anti-epithelial antibodies. Clin Exp ImmunoI8:701-711, 1971 
12. Fellner MG, Prutkin L: Morbilliform eruptions caused by penicillin. 
A study by electron microscopy and immunologic tests. J Invest 
Dermatol 55:390-395, 1970 
13. Peck SM, Osserman KE, Rule AH: Intercellular antibodies: Pres-
ence in a trichophyton rubrum infection. J Invest Dermatol 58: 
133-138, 1972 
14. Cram DL, Griffith MR, Fukuyama K: Pemphigus-like antibodies 
in cicatricial pemphigoid. Arch Dermli~ol 109:235-238, 1975 
15. Heine KG, Kumar A, Jordon RE: Pemphigus-like antibodies in 
bullous pemphigoid. Arch Dermatol 113:1693-1695, 1977 
Announcement 
Harvard Medical School, Department of Continuing Education, in conjunction with the Beth Israel 
Hospital will sponsor a one-day seminar devoted to the use of the Argon and CO2 lasers in the treatment 
of cutaneous and vascular lesions. The course will be held on September 29, 1979, in Boston, MA under 
the direction of doctors Joel M. Noe, Seymour Rosen, Kenneth Arndt, Departments of Plastic and 
Reconstructive Surgery, Pathology, and Dermatology. For additional information please contact Dr. 
Kenneth A. Arndt, 330 Brookline Avenue, Boston, MA, 02215, (617) 735-4591. 
